Exchange: NASDAQ·Updated 07:20 PM EDT

BLLNBilliontoone Inc. - Ordinary Shares - Class A

$124.53
$2.35
(1.96%)
Today
Closed $122.33
$2.20
(1.80%)
After Hours
EarningsAug 5
Mkt Cap$5.52B
Vol687,914.00
News
all
press releases
BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in...
PR Newswire
News Placeholder
More News
News Placeholder
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Here is how Biodesix, Inc. (BDSX) and BillionToOne (BLLN) have performed compared to their sector so far this year.
Zacks
News Placeholder
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
Zacks
News Placeholder
Does BillionToOne (BLLN) Have the Potential to Rally 37% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 37% in BillionToOne (BLLN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
News Placeholder
Jim Cramer on BillionToOne: I Say Buy It
Jim Cramer on BillionToOne: I Say Buy It...
Yahoo! Finance: News
News Placeholder
Cramer's lightning round: Buy BillionToOne
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...
CNBC: Mad Money with Jim Cramer
News Placeholder
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Here is how Astellas Pharma Inc. (ALPMY) and BillionToOne (BLLN) have performed compared to their sector so far this year.
Zacks
News Placeholder
Wall Street Analysts Predict a 25.63% Upside in BillionToOne (BLLN): Here's What You Should Know
The mean of analysts' price targets for BillionToOne (BLLN) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
News Placeholder
Billiontoone (NASDAQ:BLLN) Issues Earnings Results
Billiontoone (NASDAQ:BLLN - Get Free Report) released its quarterly earnings results on Wednesday. The company reported $0.34 earnings per share for the quarter, beating analysts' consensus estimates...
MarketBeat
News Placeholder
BillionToOne (BLLN) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for BillionToOne (BLLN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
<
1
2
...
>

Advertisement|Remove ads.